In last trading session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) saw 0.44 million shares changing hands with its beta currently measuring 2.97. Company’s recent per share price level of $17.77 trading at $0.85 or 5.02% at ring of the bell on the day assigns it a market valuation of $481.34M. That closing price of ARCT’s stock is at a discount of -153.24% from its 52-week high price of $45.00 and is indicating a premium of 19.53% from its 52-week low price of $14.30.

For Arcturus Therapeutics Holdings Inc (ARCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.49 in the current quarter.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information

Upright in the green during last session for gaining 5.02%, in the last five days ARCT remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $17.77 price level, adding 7.69% to its value on the day. Arcturus Therapeutics Holdings Inc’s shares saw a change of 4.71% in year-to-date performance and have moved 8.29% in past 5-day. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) showed a performance of 6.15% in past 30-days.

Wall Street analysts have assigned a consensus price target of 10.58 to the stock, which implies a fall of -67.96% to its current value. Analysts have been projecting 10.58 as a low price target for the stock while placing it at a high target of 10.58. It follows that stock’s current price would jump 40.46% in reaching the projected high whereas dropping to the targeted low would mean a gain of 40.46% for stock’s current value.

Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts

This year revenue growth is estimated to rise 2.53% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 44.64M for the same. And 6 analysts are in estimates of company making revenue of 56.24M in the next quarter. Company posted 33.99M and 38.01M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.40% during past 5 years.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders

FEDERATED HERMES, INC. is the top institutional holder at ARCT for having 4.69 million shares of worth $114.3 million. And as of 2024-06-30, it was holding 17.4067 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 2.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8262 of outstanding shares, having a total worth of $64.52 million.

On the other hand, Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.44 shares of worth $43.29 million or 8.99% of the total outstanding shares. The later fund manager was in possession of 2.2 shares on Oct 31, 2024 , making its stake of worth around $39.06 million in the company or a holder of 8.11% of company’s stock.